Engineering and characterization of a chimeric anti-platelet glycoprotein Ibα monoclonal antibody and preparation of its Fab fragment

Hybridoma

Volumn 29, Issue 2, 2010, Pages 125-132

  Yang, Jianfeng ^a   Ji, Shundong ^a   Dong, Ningzheng ^a   Zhao, Yiming ^a   Ruan, Changgeng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLATE REDUCTASE; GLYCOPROTEIN IB ALPHA; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY SZ2; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; THROMBIN RECEPTOR;

ANIMAL CELL; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; FLOW CYTOMETRY; HUMAN; HYBRIDOMA; IN VITRO STUDY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RNA EXTRACTION; SHEAR STRESS; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; WESTERN BLOTTING; ANIMAL; ANTIBODY SPECIFICITY; BIOSYNTHESIS; CHO CELL LINE; CRICETULUS; HAMSTER; IMMUNOLOGY; IMMUNOTHERAPY; MOUSE; PROCEDURES; THROMBOCYTE; THROMBOSIS;

CRICETULUS GRISEUS; MURINAE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BLOOD PLATELETS; BLOTTING, WESTERN; CHO CELLS; CRICETINAE; CRICETULUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; HYBRIDOMAS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOTHERAPY; MICE; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; THROMBOSIS;

EID: 77952056212     PISSN: 15540014     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.2009.0068     Document Type: Article

References (25)

1. Angiolillo DJ, Bhatt DL, Gurbel PA, and Jennings LK: Advances in antiplatelet therapy: agents in clinical development. Am J Cardiol 2009;103:40A-51A.
2. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, and Topol EJ: Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230-235.
3. Zimmermann N, Wenk A, Kim U, Kienzle P, Weber AA, Gams E, Schror K, and Hohlfeld T: Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003;108:542-547.
4. Muller I, Besta F, Schulz C, Massberg S, Schonig A, and Gawaz M: Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003;89:783-787.
5. Gurbel PA, Bliden KP, Hiatt BL, and O'Connor CM: Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908-2913.
6. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, and Hod H: Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-3175.
7. Massberg S, Brand K, Gruner S, Page S, Muller E, Muller I, Bergmeier W, Richter T, Lorenz M, Konrad I, Nieswandt B, and Gawaz M: A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exper Med 2002;196:887-896.
8. Ruan CG, du XP, Xi XD, Castaldi PA, and Berndt MC: A murine antiglycoprotein Ib complex monoclonal antibody, SZ 2, inhibits platelet aggregation induced by both ristocetin and collagen. Blood 1987;69:570-577.
9. Gu MB, Kern JA, Todd P, and Kompala DS: Effect of amplification of dhfr and lac Z genes on growth and betagalactosidase expression in suspension cultures of recombinant CHO cells. Cytotechnology 1992;9:237-245.
10. Zhao Y, Dong N, Shen F, Xie L, He Y, Liu F, and Ruan C: Two novel monoclonal antibodies to VWFA3 inhibit VWF-collagen and VWF-platelet interactions. J Thromb Haemost 2007;5:1963-1970.
11. Dai K, Zhu H, and Ruan C: Generation and characterization of recombinant single chain Fv antibody that recognizes platelet glycoprotein Ibalpha. Thromb Res 2003;109:137-144.
12. Merten M, and Thiagarajan P: Role for sulfatides in platelet aggregation. Circulation 2001;104:2955-2960.
13. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, and Fox KA: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-533.
14. Phillips DR, Conley PB, Sinha U, and Andre P: Therapeutic approaches in arterial thrombosis. J Thromb Haemost 2005;3:1577-1589.
15. O'Shea JC MM, Cantor WJ, Pacchiana CM, Greenberg S, Joseph DM, Kitt MM, Lorenz TJ, and Tcheng JE: use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC investigation. N Engl J Med 1994;330:956-961.
16. O'Shea JC MM, Cantor WJ, Pacchiana CM, Greenberg S, Joseph DM, Kitt MM, Lorenz TJ, and Tcheng JE: Platelet glycoprotein IIb/IIIa receptor blockade and lowdose heparin during percutaneous coronary revascularization. The EPILOG investigators. N Engl J Med 1997;336:1689-1696.
17. Lenderink T, Boersma E, Ruzyllo W, Widimsky P, Ohman EM, Armstrong PW, Wallentin L, and Simoons ML: Bleeding events with abciximab in acute coronary syndromes without early revascularization: an analysis of GUSTO IV-ACS. Am Heart J 2004;147:865-873.
18. Cauwenberghs N, Meiring M, Vauterin S, van Wyk V, Lamprecht S, Roodt JP, Novak L, Harsfalvi J, Deckmyn H, and Kotze HF: Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates. Arterioscler Thromb Vasc Biol 2000;20:1347-1353.
19. Galizia G, Lieto E, de Vita F, Orditura M, Castellano P, Troiani T, Imperatore V, and Ciardiello F: Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. Oncogene 2007;26:3654-3660. (Pubitemid 46842715)
20. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, and Lipsky P: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-1939.
21. Foran JM, Rohatiner AZ, Cunningham D, Popescu RA, Solal-Celigny P, Ghielmini M, Coiffier B, Johnson PW, Gisselbrecht C, Reyes F, Radford JA, Bessell EM, Souleau B, Benzohra A, and Lister TA: European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000;18:317-324.
22. Hwang WY, and Foote J: Immunogenicity of engineered antibodies. Methods 2005;36:3-10.
23. Shankar V, Kools JJ, Armour KL, and Clark MR: A chimeric antibody to varicella-zoster virus glycoprotein e. Hybridoma 2005;24:50-54.
24. Kim DS, Lee SH, Kim JS, Lee SC, Kwon MH, and Kim YS: Generation of humanized anti-DNA hydrolyzing catalytic antibodies by complementarity determining region grafting. Biochem Biophys Res Commun 2009;379:314-318.
25. Foote J, and Winter G: Antibody framework residues affecting the conformation of the hypervariable loops. J Mol Biol 1992;224:487-499.